EMA Recalls Ben Venue Cancer Drugs

Four cancer drugs and the antiviral medicine Vistide have been recalled owing to problems in the sterilisation process.

Four cancer drugs and the antiviral medicine Vistide have been recalled owing to problems in the sterilisation process at Ben Venue Laboratories, a US contract manufacturer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recalled bone marrow cancer drugs Busilvex and Velcade, which are produced by Ben Venue in Ohio, as a precaution.

The drugs regulator has also recalled Vidaza, used to treat some forms of leukaemia.

Breast cancer drug Caelyx, which is also manufactured by Ben Venue, will not be prescribed to preserve stocks.